pre-update Archives

Blog

4 Ways That Mechanistic Modeling Accelerates Bispecific (and Multispecific) Antibody Drug Development

With nine FDA-approved drugs today, 100+ in clinical development and several hundred in the preclinical…

Certara2024年9月12日

Conference

2024 ISSX/JSSX Meeting

Danielle Pillsbury2024年9月12日

Fact Sheet

From Protocol to Submission: Essential Regulatory Writing Resources

Danielle Pillsbury2024年9月11日

Article

Fierce Pharma – IRA biosimilar measure intended to boost uptake so far has ‘limited’ impact: report

Check out this article in Fierce Pharma to learn how Certara's US Market Access team…

Certara2024年9月11日

Poster

Dose Selection for DuoBody®-PD-L1x4-1BB (GEN1046)

Abstract DuoBody®-PD-L1x4-1BB (GEN1046) is an investigational, first-in-class, bispecific antibody designed to elicit an antitumor immune…

Renee Fisher2024年9月9日

Poster

Optimizing Avidity of Bispecific Drugs

Abstract Bispecific drugs have great potential to improve tissue selectivity through avid binding interactions but…

Renee Fisher2024年9月9日

Conference

2024 CDISC Korea Interchange

Danielle Pillsbury2024年9月9日

Poster

Effects of Tissue Targeting Bispecifics on Therapeutic Window

Abstract Objectives: The presence of target receptors in non-target tissues can reduce the therapeutic window…

Renee Fisher2024年9月9日

お知らせ

サターラ、アジア太平洋地域の医薬品開発リーダー向けにCERTAINTYフォーラム開催

Certara client forums in China, Korea, and Japan support collaboration and networking among drug developers…

Certara2024年9月3日

Publication

Application of physiologically based pharmacokinetic modeling of novel drugs approved by the U.S. food and drug administration

The article from the European Journal of Pharmaceutical Sciences reviews the role of Physiologically Based…

Danielle Pillsbury2024年9月1日

Powered by Translations.com GlobalLink Web Software

pre-update

4 Ways That Mechanistic Modeling Accelerates Bispecific (and Multispecific) Antibody Drug Development

2024 ISSX/JSSX Meeting

From Protocol to Submission: Essential Regulatory Writing Resources

Fierce Pharma – IRA biosimilar measure intended to boost uptake so far has ‘limited’ impact: report

Dose Selection for DuoBody®-PD-L1x4-1BB (GEN1046)

Optimizing Avidity of Bispecific Drugs

2024 CDISC Korea Interchange

Effects of Tissue Targeting Bispecifics on Therapeutic Window

サターラ、アジア太平洋地域の医薬品開発リーダー向けにCERTAINTYフォーラム開催

Application of physiologically based pharmacokinetic modeling of novel drugs approved by the U.S. food and drug administration

メルマガ登録

クイックアクセス

ソリューション

お問合せ